TABLE 2.
CP administration and antibody concentration
| Study | Timing | Antibody concentration | Vol | Doses | Notes | |||
|---|---|---|---|---|---|---|---|---|
| CP | Control | Donor | (ml) | |||||
| Pre | Post | |||||||
| Abolghasemi et al 17 # | ≤7 days from symptom onset | — | — | — | >1.1 | 500 | 1‐2 (24 hours apart) | — |
| Agarwal et al 24 | 8 (6–11) days from symptom onset to enrollment | — | — | — | 40 (30‐80) | 200 | 2 (24 hours apart) | Baseline NAb (50%) titer for all pts: 90 (30‐240). NAb titers similar between groups at days 0, 3, and 7. |
| Alsharidah et al 27 | CP transfusion within 24 hours of admission | — | — | — | — | 200 | 1‐2 (24 hours apart) | — |
| Altuntas et al 29 | — | — | — | — | — | ≤600 | — | — |
| Duan et al 22 | 16.5 (11.0‐19.3) days from symptom onset to CP transfusion | 320 (320‐640) | 640 (640‐640) | — | >640 | 200 | 1 | NAb (50%) |
| Gharbharan et al 18 | 10 (6‐15) days from symptom onset to time of inclusion | 320 (20‐1280) | — | 80 (20‐640) | 640 (320‐1280) | 300 | 1–2 (5 days apart) | NAb (50%) |
| Hegerova et al 19 | 2 (1‐4.3) days from hospitalization to CP transfusion | — | — | — | — | — | — | — |
| Li et al 20 * | 30 (20‐39) days from symptom onset to randomization | — | — | — | ≥640 | 4–13 mL/kg | — | — |
| Liu et al 23 * | 7 (range 0‐14) days from symptom onset to initial presentation. 4 (range 0‐7) days from admission to CP transfusion | — | — | — | ≥320 | 500 | — | — |
| Omrani et al 28 |
10 (9‐10) days from symptom onset to CP transfusion |
— | — | — | — | 400 | — | — |
| Rasheed et al 25 # | 14.8 ± 7.5 days infected to study inclusion | — | — | — | ≥1.25 | — | — | — |
| Rogers et al 30 # | 7 (5‐9) days from symptom onset to CP transfusion | — | — | — | Variable | — | 1‐2 |
50% of pts received CP with AI ≥1.4. 28% of pts received CP with AI ≥5.0. 13% of pts received CP with AI <1.4. |
| Salazar et al 31 * | — | — | — | — | ≥1350 | 300 | 1‐2 | 7% of pts received CP with IgG 150‐1350 and 2% received CP with IgG <150. |
| Simonovich et al 26 * | 8 (5‐10) days from symptom onset to enrollment | 50 (0‐800) | 400 (200‐1600) | 50 (0–1600) |
IgG:3200 (800‐3200) NAb: 300 (136‐511) |
500 (415‐600) | — | 65% of total pts had baseline IgG data. 56% of donors had NAb (80%) titers evaluated. |
| Zeng et al 21 | 21.5 (17.8‐23) days of viral shedding before treatment | — | — | — | — | 300 (200‐600) | — | — |
Note: Timing of CP administration is presented as median (IQR) or mean ± SD unless otherwise indicated. Neutralizing antibody (NAb) titers are presented unless otherwise indicated (*IgG, # IgG index). Titers (NAb, IgG; 1:#) or IgG indexes are expressed as median (IQR) or as a single value expressing the minimum concentration used for transfusion (Donor). Data from patients in the convalescent plasma cohort (CP) are provided as baseline (Pre) or after treatment (Post) levels. NAb (%): percentage of virus neutralized.
Abbreviations: AI, antibody index; Pts, patients.